Swiss Medica Expands Media Coverage For O24'TM' Essential Oil Pain Neutralizer Product To Meet Consumer Demand.TORONTO -- Grant Johnson, President and COO of Swiss Medica medica (māˑ·dē·k (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :SWME), is pleased to announce expanded media coverage and upcoming events for the Company's flagship product A primary product of a company, which is typically why the company was founded and/or what made it well known. For example, MS-DOS, Windows and the Microsoft Office suite have been flagship products of Microsoft. CorelDRAW is a flagship product of Corel Corporation. , the O24(TM) Essential Oil Pain Neutralizer, now that the Company is experiencing increasing demand and Canadian retail re-orders for our product. Swiss Medica has begun posting an Event Calendar on the Company's website, which will be regularly updated with talk show appearances, conferences and events. To see our Calendar, please go to www.swissmedica.com, click on "Investor Relations Investor relations The process by which the corporation communicates with its investors. , and then click on "Calendar." Swiss Medica has also posted a 24-page Investor Information Guide on the Company's website: http://www.swissmedica.com/investorguide.pdf Starting on October 2nd, Swiss Medica spokesmen will begin appearing on a substantial number of one-hour live AM radio talk shows in selected Canadian cities. These cities include larger metropolitan areas, such as Toronto, Montreal, Vancouver, and Ottawa. Smaller cities, such as Halifax (Nova Scotia Nova Scotia (nō`və skō`shə) [Lat.,=new Scotland], province (2001 pop. 908,007), 21,425 sq mi (55,491 sq km), E Canada. Geography ) and key Ontario cities, such as Peterborough, Windsor, London and Kitchener-Waterloo, were selected because of strong retail presence of the O24(TM) product in those cities. Shareholders may wish to listen to these live radio talk show appearances via the Internet, where applicable, by visiting the Swiss Medica events calendar and checking times and dates. Throughout October, Swiss Medica has contracted to have in-store demonstrations of the O24(TM) product in 250 leading pharmacies across Canada. This is to help educate pharmacists and consumers about our flagship product's different applications for various body ailments. On October 14th to 16th, Swiss Medica will debut the O24(TM) product to the US consumer market at the American Association for Retired People's (AARP AARP, a nonprofit, nonpartisan national organization dedicated to "enriching the experience of aging"; membership is open to people age 50 or older. Founded in 1958 by Ethel Percy Andrus as American Association of Retired Persons, AARP now has over 30 million ) national event in Las Vegas, Nevada. Dr. E. Michael Gutman will speak about the O24(TM) product's pain relief qualities and efficacy for fibromyalgia fibromyalgia Chronic syndrome that is characterized by musculoskeletal pain, often at multiple sites. The cause is unknown. A significant number of persons with fibromyalgia also have mental disorders, especially depression. and arthritic pains. More than 20,000 AARP members and guests are expected to attend this national event. About Swiss Medica Inc. Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.024zone.com. Forward-looking statements in this news release are made pursuant to the "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion